Biora Therapeutics announced the issuance of a new patent related to the company’s BioJet platform for oral, systemic delivery of biotherapeutics, which uses an ingestible device designed to achieve systemic uptake through liquid jet delivery to the small intestine. The United States Patent and Trademark Office has issued U.S. Patent No. 11,938,295 entitled, “Ingestible Device for Delivery of Therapeutic Agent to the Gastrointestinal Tract.” The issued claims cover key jet parameters for liquid jet delivery of a drug to the gastrointestinal tract, including the stomach or small intestine.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIOR:
- Biora Therapeutics announces interim results of BT-600 clinical trial
- Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
- Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Biora Therapeutics prices 5.45M shares at $1.10 in registered direct offering
- Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
